← back to search

Fiona Taylor

London School of Hygiene & Tropical Medicine · GB
🔎 Find collaborators in Oncology · Economics and Econometrics →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Economics and Econometrics
Research interest
Research focused on Nivolumab and Cochrane Library, with related work in Phase (matter), Disease, Interim analysis. Notable publications include 'Statins for the primary prevention of cardiovascular disease', 'Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related...', and 'Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial'.
h-index
citations
3,526
works
17
NIH funding
primary concept
email

Recent publications

Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms
Orphanet Journal of Rare Diseases 2023cited by 6position: middledoi
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©
Orphanet Journal of Rare Diseases 2021cited by 21position: firstdoi
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study
Orphanet Journal of Rare Diseases 2021cited by 16position: middledoi
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
The Lancet Oncology 2017cited by 424position: middledoi
Health-related quality of life results from the phase III CheckMate 067 study
European Journal of Cancer 2017cited by 95position: middledoi
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
The Lancet Oncology 2016cited by 218position: middledoi
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
Annals of Oncology 2016cited by 118position: middledoi
Multiple Risk Factor Interventions for Primary Prevention of CVD in LMIC: A Cochrane Review
Global Heart 2016cited by 15position: middledoi
Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Cochrane Database of Systematic Reviews 2015cited by 95position: middledoi
Promoting patient uptake and adherence in cardiac rehabilitation
Cochrane Database of Systematic Reviews 2014cited by 207position: middledoi
Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis
BMC Medicine 2014cited by 183position: middledoi
Reduced dietary salt for the prevention of cardiovascular disease
Cochrane Database of Systematic Reviews 2014cited by 128position: middledoi
Huffman and colleagues' response to Abramson and colleagues' article on statins in low risk people
BMJ 2014cited by 5position: middledoi
Statins for the primary prevention of cardiovascular disease
Cochrane Database of Systematic Reviews 2013cited by 1,833position: firstdoi
Statin Therapy for Primary Prevention of Cardiovascular Disease
JAMA 2013cited by 142position: firstdoi
FOOD ACQUISITION AND INTRA-HOUSEHOLD CONSUMPTION PATTERNS: A STUDY OF LOW AND MIDDLE INCOME URBAN HOUSEHOLDS IN DELHI, INDIA.
PubMed 2013cited by 9position: middle
Statins Work Just as Well in Women as in Men
Archives of Internal Medicine 2012cited by 11position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Shah Ebrahim · London School of Hygiene & Tropical Medicine10 papers (2012–2016)Anthony Boral · Novartis (Switzerland)3 papers (2021–2023) · 3 papers (2021–2023)Brenton G. Mar · Xilio Therapeutics (United States)3 papers (2021–2023) · 3 papers (2021–2023) · 3 papers (2021–2023)Frank Siebenhaar · Humboldt-Universität zu Berlin3 papers (2021–2023)Mark D. Huffman · Northwestern University3 papers (2013–2014)Cem Akin · University of Michigan3 papers (2021–2023)Aileen Clarke · Cardiff University2 papers (2015–2016)Ana Filipa Macedo · London School of Hygiene & Tropical Medicine2 papers (2013–2014) · 2 papers (2016–2017)Viktor Grünwald · Dana-Farber Cancer Institute2 papers (2016–2017)Nicole Martin · Hospital for Sick Children2 papers (2014–2014)Karen Rees · University of Warwick2 papers (2015–2016)Louise Hartley · University of Warwick2 papers (2015–2016)Olalekan A. Uthman · University of Warwick2 papers (2015–2016)Georgina V. Long · ARC Centre of Excellence in Synthetic Biology2 papers (2016–2017) · 2 papers (2016–2016)Piotr Rutkowski · Maria Curie-Skłodowska University2 papers (2016–2017)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Economics and Econometrics →